• 1
    Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002; 298: 78991.
  • 2
    Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs. 2011; 71: 203165.
  • 3
    Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21: 383421.
  • 4
    Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease–a double-edged sword. Neuron. 2002; 35: 41932.
  • 5
    Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012; 9: 8.
  • 6
    Yoo KY, Park SY. Terpenoids as potential anti-Alzheimer's disease therapeutics. Molecules. 2012; 17: 352438.
  • 7
    Dao TT, Le TV, Nguyen PH, et al. SIRT1 inhibitory diterpenoids from the Vietnamese medicinal plant Croton tonkinensis. Planta Med. 2010; 76: 10114.
  • 8
    Kume T, Katsuki H, Akaike A. Endogenous factors regulating neuronal death induced by radical stress. Biol Pharm Bull. 2004; 27: 9647.
  • 9
    Ren Y, Houghton PJ, Hider RC, et al. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med. 2004; 70: 2014.
  • 10
    Zhang Z, Zhang X, Xue W, et al. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line. Int J Nanomedicine. 2010; 5: 73542.
  • 11
    Ji Z, Tang Q, Zhang J, et al. Oridonin-induced apoptosis in SW620 human colorectal adenocarcinoma cells. Oncol Lett. 2011; 2: 13037.
  • 12
    Jia L, Shen J, Zhang D, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012; 50: 5239.
  • 13
    Liu J, Yang F, Zhang Y, et al. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra. Int Immunopharmacol. 2007; 7: 94554.
  • 14
    Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med. 2012; 13: 717.
  • 15
    Xu Y, Xue Y, Wang Y, et al. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009; 9: 3605.
  • 16
    Gengler S, Hamilton A, Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS ONE. 2010; 5: e9764.
  • 17
    Radde R, Bolmont T, Kaeser SA, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006; 7: 9406.
  • 18
    Wesson DW, Wilson DA. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res. 2011; 216: 40813.
  • 19
    Hibbits N, Pannu R, Wu TJ, et al. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro. 2009; 1: e00013.
  • 20
    Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res. 2007; 176: 216.
  • 21
    Zhang Z, Zhang ZY, Fauser U, et al. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol. 2008; 210: 68190.
  • 22
    Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther. 2005; 4: 57886.
  • 23
    Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol. 2005; 68: 28697.
  • 24
    Hu AP, Du JM, Li JY, et al. Oridonin promotes CD4+/CD25+ Treg differentiation, modulates Th1/Th2 balance and induces HO-1 in rat splenic lymphocytes. Inflamm Res. 2008; 57: 16370.
  • 25
    Tweedie D, Ferguson RA, Fishman K, et al. Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation. 2012; 9: 106.
  • 26
    Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des. 2010; 16: 276678.
  • 27
    Patel NS, Paris D, Mathura V, et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation. 2005; 2: 9.
  • 28
    Paris D, Patel N, Quadros A, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007; 415: 116.
  • 29
    Ownby RL. Neuroinflammation and cognitive aging. Curr Psychiatry Rep. 2010; 12: 3945.
  • 30
    Alexander G, Hanna A, Serna V, et al. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Behav Brain Res. 2011; 216: 7783.
  • 31
    Filali M, Lalonde R, Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav. 2011; 104: 8805.
  • 32
    Pietropaolo S, Delage P, Lebreton F, et al. Early development of social deficits in APP and APP-PS1 mice. Neurobiol Aging. 2012; 33: 1002, e1727.
  • 33
    Sivilia S, Lorenzini L, Giuliani A, et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 2013; 14: 44.
  • 34
    Medeiros R, Kitazawa M, Passos GF, et al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol. 2013; 182: 17809.
  • 35
    Shindo T, Takasaki K, Uchida K, et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull. 2012; 35: 21417.
  • 36
    Choi SH, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem. 2013; 124: 5968.
  • 37
    Biscaro B, Lindvall O, Tesco G, et al. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis. 2012; 9: 18798.
  • 38
    Dai W, Zhang D, Duan C, et al. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul. 2010; 27: 23441.
  • 39
    Ganta S, Deshpande D, Korde A, et al. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010; 27: 26073.